Learn the 7 most critical considerations when sourcing mRNA for vaccine or therapy development

Messenger RNA (mRNA) vaccines and therapies are emerging as the next major advance in the history of drug development. Interest and investment in the new drug class have intensified since mRNA COVID-19 vaccines validated the technology, driving increased demand for the nucleic acid.1-3 Multiple companies are serving that demand, but there are important differences between the mRNA and services they provide.

mRNA is made in a four-step process: Linear plasmid production, in vitro transcription (IVT), purification and final quality control. While production is relatively simple, the process must be tightly controlled. Manufacturers must control critical quality attributes to ensure consistency. Failure to do so results in lot-to-lot variability that can cause expensive, time-consuming delays to the development of investigational candidates and introduce safety risks in the manufacture of finished products.

The potential for poor mRNA quality to delay access to life-changing medicines and—in the case of smaller, loss-making startups—potentially bankrupt businesses makes the choice of a reliable mRNA supplier vital. Here, we look at the seven critical factors that companies should consider when seeking to source high-quality modified mRNA at the scale and grade needed to succeed.

Learn the 7 most critical considerations when sourcing mRNA for vaccine or therapy development; including plasmid DNA integrity, polyA tail consistency, capping options, uridine modification, LNP packaging, manufacturing workflow, QA/QC, and more.

Whitepaper Highlights:

Effects of plasmid DNA integrity on mRNA quality

Production strategies for improved PolyA tail consistency

mRNA capping options for different cell types

Importance of uridine modification

LNP packaging strategies for improved mRNA delivery

Benefits of integrated manufacturing workflow & customizable QA/QC options

Download now: http://ow.ly/JAKs50OgxNs

Place a quick order here: http://ow.ly/pLaZ50OgxLl